Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

NCT03256344 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03256344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03256344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2018
Completion date
December 3, 2021
Enrollment
36 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer, metastatic triple negative breast cancer